STOCK TITAN
  1. Home
  2. News
  3. CTSO

Cytosorbents Corp - CTSO STOCK NEWS

Welcome to our dedicated news page for Cytosorbents (Ticker: CTSO), a resource for investors and traders seeking the latest updates and insights on Cytosorbents.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cytosorbents's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cytosorbents's position in the market.

News
STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
Rhea-AI Summary
CytoSorbents (NASDAQ: CTSO) announced that the topline results from its STAR-T pivotal trial will be presented at the 2024 American Association for Thoracic Surgery Annual Meeting. The presentation will focus on the safety and efficacy of intraoperative removal of Ticagrelor in patients undergoing urgent cardiac surgery. Following the event, a Virtual KOL and Investor Day will be held to review the trial results and discuss real-world usage of CytoSorb®.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
Rhea-AI Summary
CytoSorbents reported positive financial results for the year 2023, with total revenue increasing by 5% to $36.3 million. Product sales saw a 6% growth to $31.1 million, driven by a 10% increase in core CytoSorb sales. Product gross margins improved to 72%, and cumulative CytoSorb treatments surpassed 228,000. The STAR-T trial results were selected for a Breakout Presentation at the AATS Annual Meeting, with plans to submit DrugSorb-ATR for regulatory approval to the FDA and Health Canada in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.27%
Tags
earnings
-
News
CytoSorbents to Report Fiscal 2023 Operating and Financial Results
Rhea-AI Summary
CytoSorbents Corporation (CTSO) will report fiscal 2023 financial results on March 14th, 2024. The live conference call will discuss operational and financial progress during Q4 2023 and fiscal year ending December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.77%
Tags
conferences earnings
News
CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference
Rhea-AI Summary
CytoSorbents Corporation (NASDAQ: CTSO) CEO, Dr. Phillip Chan, to present at TD Cowen 44th Annual Health Care Conference in Boston. The company will also hold in-person meetings with investors during the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News
Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients
Rhea-AI Summary
CytoSorbents Corporation (NASDAQ: CTSO) reports statistically significant reductions in multiple organ failure and dysfunction in heart transplant patients using CytoSorb® blood purification. The groundbreaking randomized controlled trial (RCT) published in the European Society of Cardiology journal, ESC Heart Failure, showed that patients who received CytoSorb had better hemodynamic stability, lower rates of post-operative shock, shorter time on mechanical ventilation, lower rates of acute kidney injury, and shorter time in the ICU. The study also revealed similar rates of cardiac allograft rejection, 30-day mortality, and 1-year survival between the CytoSorb group and the control group.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation
Rhea-AI Summary
CytoSorbents Corporation (NASDAQ: CTSO) announces an update on the initial data analysis of primary safety and effectiveness endpoints and the final independent Data and Safety Monitoring Board analysis for the pivotal U.S. and Canadian STAR-T trial. The study did not meet the primary effectiveness endpoint in the overall patient population undergoing different types of cardiac surgeries, but demonstrated evidence of reduced bleeding complications in patients undergoing isolated coronary artery bypass graft surgery. The safety and effectiveness data may support the regulatory submission of DrugSorb-ATR to the U.S. FDA and Health Canada. The full results of the STAR-T trial are expected to be presented at the American College of Cardiology 2024 conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-33.44%
Tags
none
News
CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering
Rhea-AI Summary
CytoSorbents Corporation (NASDAQ: CTSO) announces the closing of a registered direct offering, raising approximately $9.83 million in net proceeds. The offering included the sale of 7,733,090 shares of registered common stock and warrants to purchase up to 2,706,561 shares of common stock. The company's executive officers, directors, and certain non-executive officer employees also participated in the financing with a combined investment of $435,000. The net proceeds will be used for general corporate purposes, including funding clinical and regulatory efforts, supporting growth initiatives, investing in clinical studies, and funding ongoing R&D initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.53%
Tags
offering
-
News
CytoSorbents Reports Third Quarter 2023 Financial and Operational Results
Rhea-AI Summary
CytoSorbents Corporation (NASDAQ: CTSO) reported unaudited Q3 2023 financial results, including a 20% increase in product sales to $7.8M, total revenue of $8.8M, and a 72% product gross margin. The pivotal STAR-T trial remains blinded, with initial data analysis completion expected before year-end.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
earnings
-
News
CytoSorbents to Report Third Quarter 2023 Operating and Financial Results
Rhea-AI Summary
CytoSorbents Corporation (NASDAQ: CTSO) will report its third quarter 2023 operating and financial results on November 9th, 2023. A live presentation webcast and Q&A session will be held at 4:30 PM EDT on the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.83%
Tags
conferences earnings
News
CytoSorbents to Present at the 8th Annual Dawson James Conference
Rhea-AI Summary
CytoSorbents Corporation CEO to present at Dawson James Small Cap Growth conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.73%
Tags
conferences
Stock CTSO logo
Cytosorbents Corp

Nasdaq:CTSO

CTSO Rankings

#4739 Ranked by Market Cap
#3208 Ranked by Stock Gains
N/A Ranked by Dividends

CTSO Stock Data

47.34M
46.68M
9.75%
39.53%
2.98%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Monmouth Junction

About CTSO

cytosorbents (nasdaq: ctso) cytosorbents corporation is a leader in critical care immunotherapy, specializing in blood purification. its flagship product, cytosorb® is approved in the european union with distribution in 40 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm"​ or "cytokine release syndrome"​ that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury and pancreatitis, as well as in cancer immunotherapy. these are conditions where the risk of death is extremely high, yet no effective treatments exist. cytosorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. cytosorbents'​ purification technologies are based on biocompatible, highly porous polymer beads